16th Annual Scientific Meeting - LWW Journalsjournals.lww.com/jcnjournal/Documents/69832 HFSA Advance Program_lo.pdfThe 16th Annual Scientific Meeting of the Heart Failure Society

September 9 – 12, 2012Washington State Convention Center

Seattle, WAwww.hfsa.org

16th Annual Scientific Meeting Advance Program & Registration Information

332

advance program advance program

Highlights of the 2012 HFSa annual Scientific meeting ❚ Popular reviews of Clinical Fundamentals updated for 2012

❚ Excellence in Basic Science featuring Eric N. Olson on Strategies to Repair the Ailing Heart

❚ Plenary session focusing on communication — from electronic feedback loops to laureate poetry

❚ Oral Abstract Presentations including new Featured Oral Session plus two noon-time rapid-fire sessions — basic science, clinical, and nursing

❚ Joint ICCAC-VAD session from consent through outcomes and lessons learned from myVAD.com

❚ How-to sessions ranging from trendy — Using Apps for Self-Care to timeless — Difficult Conversations About Prognosis

❚ U-Shaped Curves in Heart Failure — What are they?

❚ A two-part study session on the MOC self-evaluation module in Advanced Heart Failure and Transplant Cardiology

❚ Strategies for National Heart Failure Care and Envisioning Therapy in Heart Failure with commentary by Eugene Braunwald offer wide views of what’s ahead

❚ Focus on the Readmission Challenge, Performance Measures, and Drug-Device Approval Processes in the U.S.

❚ A Day In The Life from translational clocks to medication schedules for the patient with heart failure.

❚ Integrated basic science from The Human Genome Comes Home to How Should We Improve Pump Function?

❚ Controversies exposed: Reducing Sodium: Fact or Fiction?; Adult Stem Cells vs iPS Cells or Real Recovery with VADs?; Three Treatments for Atrial Fibrillation; and Implantable vs Non-invasive Home Monitoring.

❚ And, of course, Case Discussions, Hyde Park, Late-Breaking Science, Debates, Posters, Satellite Symposia, Product Theaters, Hands-on Device Workshops, and more — all in the beautiful city of Seattle!

open plenary guest Speakers

Thomas Goetz is author of The Decision Tree: Taking Control of Your Health in the New Era of Personalized Medicine. Former FDA commissioner Dr. David Kessler calls The Decision Tree “a game changer,” and Dr. Dean Ornish says that Goetz “writes more clearly and presciently about the future of health care than anyone on the planet.” The executive editor of WIRED Magazine, Goetz writes frequently on the confluence of medicine, health and technology. His cover stories at WIRED have covered the early detection of cancer, the advent of personal genomics and the controversial diagnosis of metabolic syndrome. His work has been selected for both the Best American Science Writing and the Best Technology Writing anthologies. Since Goetz joined WIRED in 2001, the magazine has been nominated for 12 National Magazine Awards and has won six times, including the top award for general excellence three times.

Billy Collins is an American phenomenon. No poet since Robert Frost has managed to combine high critical acclaim with such broad popular appeal. His work has appeared in a variety of periodicals including The New Yorker, The Paris Review and The American Scholar, and he is a Guggenheim fellow and a New York Public Library “Literary Lion.” His last three collections of poems have broken sales records for poetry. His readings are usually standing room only, and his audience – enhanced tremendously by his appearances on National Public Radio – includes people of all backgrounds and age groups. The poems themselves best explain this phenomenon. The typical Collins poem opens on a clear and hospitable note but soon takes an unexpected turn; poems that begin in irony may end in a moment of lyric surprise. No wonder Collins sees his poetry as “a form of travel writing” and considers humor “a door into the serious.” It is a door that many thousands of readers have opened with amazement and delight.

Billy Collins has published nine collections of poetry and was United States Poet Laureate 2001-2003.

general InformationThe 16th Annual Scientific Meeting of the Heart Failure Society of America offers a diverse program including basic science, translational and clinical sessions. There is something for everyone interested in heart failure. Register before July 30 to receive a discount.

Expected AttendeesIt is anticipated that attendees will include: ❚ Cardiologists, CV surgeons, internists and primary care physicians ❚ Clinical researchers ❚ Cardiac rehabilitation professionals ❚ Cardiac care nurses ❚ Epidemiologists ❚ Health care administrators ❚ Industry ❚ Pharmacists ❚ Research scientists

Visas/Letters of Invitation

If you have visa requirements it is highly recommended that you begin the process soon. Letters of invitation for visa purposes will be provided by the HFSA office upon request. Please email your request to [email protected]. It should be understood that the letter of invitation is meant to help members obtain a visa and is not a commitment on the part of the organizers to provide any financial support. The decision to grant a visa belongs solely to the embassy/consulate. Should your application be denied, HFSA cannot change the decision of the government agency.

Special NeedsThe HFSA strives to hold meetings that are accessible to all. Please tell us what you require to help make your participation more enjoyable and meaningful. Contact Gudrun Echterhoff, Global Meetings & Incentives at [email protected] ((201) 850-7607).

Liability Statement

Disclaimer: The Heart Failure Society of America (HFSA) cannot accept, and hereby specifically disclaims, any liability for death, injury, any loss, cost or expense suffered or incurred by any person if such loss is caused by, arises from or results from the act, default or omission of any person other than an employee or agent of HFSA. In particular, neither HFSA nor its agents can accept, and hereby specifically disclaims, any liability for losses arising from, caused by, or resulting from, the provision or non-provision of services provided by the hotels, companies, or transport operators. Neither HFSA nor its agents can accept, and hereby specifically disclaims, liability for losses suffered by reason of war including threat of war, riots and civil strife, terrorist activity, natural disaster, weather, fire, flood, drought, technical, mechanical or electrical breakdown within any premises visited by delegates and/or participants in connection with the meeting, industrial disputes, government action, regulations or technical problems that affect or may affect the services provided in connection with the meeting. HFSA is not able to warrant and does not warrant that a particular person will appear as a speaker. As a condition to any participation in or attendance at the Annual Scientific Meeting or any function associated or affiliated herewith, each attendee and participant accepts the foregoing disclaimer.

executive councilOfficersBarry M. Massie, MD (President)Thomas Force, MD (Vice-President)Hani N. Sabbah, PhD (Secretary)Mandeep R. Mehra, MD (Treasurer)Douglas L. Mann, MD (Immediate Past President)

MembersInder S. Anand, MD, PhDJohn C. Burnett, Jr., MDJohn Chin, MDSteven R. Houser, PhDSharon A. Hunt, MDJoAnn Lindenfeld, MDSara C. Paul, DNP, FNPMariann Piano, RN, PhDHeather J. Ross, MDRandall C. Starling, MD, MPHJames E. Udelson, MDMichael R. Zile, MD

Members (ex officio)Jay N. Cohn, MDGary S. Francis, MDDavid A. Lathrop, PhDIsabella Liang, PhD

2012 Scientific Program CommitteeLynne Warner Stevenson, MDSteven R. Houser, PhDBarbara J. Riegel, DNSc, FANN, FAHALarry A. Allen, MD, MHSMark E. Anderson, MD, PhDBikyem Bozkurt, MDHarleah G. Buck, RN, PhD, CHPNAkshay S. Desai, MDDaniel E. Forman, MDJalal K. Ghali, MDJoshua I. Goldhaber, MDJ. Thomas Heywood, MDCorrine Y. Jurgens, RN, PhDChristopher Lee, RN, PhDAnnarosa Leri, MDWayne C. Levy, MDDouglas W. Losordo, MDLeslie W. Miller, MDRobert Lee Page, II, PharmD, MSPHMichael G. Petty, RN, CCNS, ACNSMargaret M. Redfield, MDPaul B. Rosenberg, MDDouglas D. Schocken, MDJagmeet P. Singh, MD, PhDYibin Wang, PhD

HFSA Corporate MembersAmgenBoston ScientificJanssen Scientific AffairsMedtronic, Inc.Otsuka PharmaceuticalsSt. Jude MedicalThoratec Corporation

about HFSaThe Heart Failure Society of America (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart failure research and patient care.

The HFSA is dedicated to: ❚ Promoting research related to all aspects of heart failure and to providing a forum

for presentation of basic, clinical and population-based research.

❚ Educating health care professionals through programs, publications and other media in the areas of basic science, clinical medicine, patient management, and social, ethical and economic issues to enable them to diagnose and treat heart failure and concomitant medical conditions more effectively.

❚ Encouraging primary and secondary preventive measures to reduce the incidence of heart failure; serving as a resource for government, private industry and health care providers to facilitate the establishment of programs and policies that will better serve the patient.

❚ Enhancing quality and duration of life in those with heart failure.

❚ Promoting and facilitating the formal training of physicians, scientists and allied health care providers in the field of heart failure.

membership InformationMembership in the Society is open to all health care professionals with an interest in cardiovascular medicine. For information about the HFSA and how to become a member, visit the HFSA website: www.hfsa.org.

For questions, contact:Heart Failure Society of America (HFSA) Court International, Suite 240 South 2550 University Avenue West St. Paul, MN 55114Phone: (651) 642-1633 Fax: (651) 642-1502 Email: [email protected] Website: www.hfsa.org

554

advance program

Attractions

The 605-foot-high Space Needle, built for the 1962 World’s Fair, is Seattle’s number one tourist destination. It provides one of the best views of the city, the Puget Sound and the surrounding mountains. A visit to Seattle wouldn’t be complete without a stop at Pike Place Market. The famous attraction occupies a 9-acre area along the water and features fresh local produce, food, crafts and gifts. Don’t miss the fishmongers and catchers at the market who entertain visitors by tossing around fish to each other across their stands.

Arts & Culture

The Seattle Art Museum features an outstanding permanent collection and an ever-changing rotation of special exhibits from around the world. The Henry Art Gallery is home to exciting new works, while the Frye Art Museum serves up both classic and contemporary paintings. The nation’s finest collections of Korean, Chinese and Japanese art are housed at the Seattle Asian Art Museum in Volunteer Park and the original Air Force One is displayed at the popular Museum of Flight.

Restaurants

Seattle’s diverse population and proximity to the Puget Sound contribute to some of the best seafood, sushi and Japanese food in the Pacific Northwest. If seafood is not your thing, there is an abundance of cuisines from which to choose. From upscale steakhouses and Italian restaurants to welcoming coffee shops — including the original Starbucks — and specialty bakeries, the city is awash with casual and fine dining establishments to satisfy any palette.

Shopping

Downtown Seattle features all the brand names you know and love, including Nordstrom, Gap, J. Crew and Ann Taylor, while the Fremont shopping district is a haven for lovers of retro and vintage shops. The International District, or the ID as it’s known, is just southeast of Pioneer Square and highlights the tastes and sights of Asia. Pike Place is the place to go for handmade arts, crafts and other local wares. And, as its name implies, the university area caters to the University of Washington’s collegiate crowd with cheap eats and a mix of chain stores and boutiques.

Conference Location

The 16th Annual Scientific Meeting of the Heart Failure Society of America will be held at the Washington State Convention Center in Seattle, WA. Located in the heart of downtown Seattle, the Center features on-site parking, business services and a variety of eateries — all within easy walking distance of the city’s best shops, sights, hotels and restaurants.

Hotel

The Sheraton Seattle Hotel & Towers is located within walking distance of the Washington State Convention Center and blocks from Seattle’s famed Pike Place Market. The hotel features a newly remodeled fitness center, expanded lobby, stylish guest rooms, indoor swimming pool, business center, restaurants and much more.

Sheraton Seattle Hotel & Towers (Headquarter Hotel)1400 Sixth AvenueSeattle, WA 98101(206) 621-9000

Rates: $249 Single/Double Occupancy, $269 Deluxe Room, $289 Club Level, $25 Additional Person

Taxes: 15.60%

These rates include in-room high-speed Internet access for all guests blocked within the HFSA room block.

Register Online

Registration for the 16th Annual Scientific Meeting of the Heart Failure Society of America is available online at: hfsa.org/registration_info.asp. Online registration requires a credit card. If you do not wish to register online, you may fill out the form on page 26 of this brochure and return the form by mail with payment to: HFSA, Court International, Suite 240 South, 2550 University Avenue West, St. Paul, MN 55114.

Registration Fee

The registration fee includes admittance to all meeting events, including scientific sessions, opening reception, poster sessions, satellite symposia and commercial exhibits.

MOC (Maintenance of Certification): Attendees will need to preregister for these sessions. Details will be provided at a later date.

registration and exhibit Hours

Registration HoursSaturday September 8 1:00 PM – 4:00 PM

Sunday September 9 8:00 AM – 5:00 PM

Monday September 10 7:00 AM – 5:00 PM

Tuesday September 11 7:00 AM – 5:00 PM

Wednesday September 12 7:00 AM – 10:00 AM

Exhibit HoursSunday September 9 6:00 PM – 8:00 PM

Monday September 10 9:30 AM – 7:00 PM

Tuesday September 11 9:30 AM – 7:00 PM

An application to exhibit and an exhibit prospectus may be obtained by contacting the HFSA at [email protected], (651) 642-1633/fax: (651) 642-1502. You may also download a copy at hfsa.org (annual scientific meeting).

SeaTTLe: a deSTInaTIon

ACTTheatre

FE

Office Tower

EntranceEntrance Entrance

ecnartnE

To/FromACT

$

Levels 1-4and

to North Lobby

Levels 1-4and to

South Lobby

niat nuoF

SouthGalleria Retail

BusinessCenter

i

Retail

Retail

TDD

10

Entrance

Entranc

e

Entrance

ht 7A

eunev

Pike Street

Union Street

ToConvention

CenterParkingGarage

Entrance

FE

FE

FE

FE

N

776

advance program

ce Information

Learning ObjectivesFollowing this meeting, participants will be able to:

❚ Describe the epidemiology of heart failure and implement strategies for the prevention of heart failure.

❚ Describe current knowledge about the scientific basis of heart failure at the levels of cardiovascular physiology, neurohormones, tissue factors, and molecular biology and genetics.

❚ Identify the findings of basic science and current clinical trials and discuss their implications for current and future heart failure therapy.

❚ Implement optimal guideline-based therapeutic options for heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and device-based therapies.

❚ Manage comorbidities, including hypertension, diabetes and depression.

❚ Demonstrate awareness of psychosocial, economic and ethical issues in the treatment of patients with heart failure.

❚ Implement strategies for effective management of the patient with heart failure, incorporating the family, encouraging self-care and employing the medical home model.

❚ Outline strategies for transitioning patients from inpatient to outpatient care and for reducing hospital readmissions.

❚ Engage in performance measurement and other site-based research.

❚ Communicate effectively with patients, families and other health professionals.

Individual session objectives are listed after each session in the program book.

Scientific Program

The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Heart Failure Society of America designates this live activity for a maximum of 25 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program has been approved by the American Association of Critical Care Nurses (AACN) for 24.5 Contact Hours, Synergy CERP Category A, File number 00017881.

Badges will be scanned automatically as attendees enter a session, including satellite symposia. This information will be used to verify attendance for CME and CNE credits and will not be sold or shared with anyone outside the HFSA.

Satellite Symposia

Credit will be provided for physicians and nurses. Two-hour satellites provide 2 hours of credit; 1-hour satellites provide 1 hour.

Poster Sessions

Poster sessions provide an opportunity for interaction between the poster authors and attendees. Posters are listed in the final program booklet and are on display Monday, September 10, and Tuesday, September 11, 9:30 AM - 7:00 PM. Authors will be at their posters both days from 5:45-6:45 PM.

Satellite Symposia

These one- or two-hour symposia, often focusing on recent research and emerging therapeutic options, are planned using the same criteria that apply to the scientific program. They are reviewed and approved by the HFSA Satellite Symposium Review Committee and provide CME and CNE credit.

Satellite attendees must be registered for the Annual Scientific Meeting. No additional registration or fee is required. Satellites are held Sunday afternoon and Monday and Tuesday mornings.

Information about satellite symposia will be posted online at www.hfsa.org as programs are finalized. All satellite symposia are included in the final program book.

Keith D. Aaronson, MD, MSUniversity of MichiganAnn Arbor, MI

William T. Abraham, MDThe Ohio State UniversityColumbus, OH

Michael A. Acker, MDUniversity of PennsylvaniaPhiladelphia, PA

Philip B. Adamson, MDOklahoma Heart HospitalOklahoma City, OK

Felipe Aguel, PhDFood and Drug Administration/CDRHSilver Spring, MD

David Aguilar, MDBaylor College of MedicineHouston, TX

Ali Ahmed, MD, MPHUniversity of Alabama at BirminghamBirmingham, AL

Nancy M. Albert, RN, PhDCleveland Clinic FoundationCleveland, OH

Larry A. Allen, MD, MHSUniversity of ColoradoAurora, CO

Inder S. Anand, MD, PhDMinneapolis VAMCMinneapolis, MN

Stefan D. Anker, MD, PhDCharite, Campus Virchow-KlinikumBerlin, Germany

Ross Arena, PT, PhDThe University of New MexicoAlbuquerque, NM

Gust H. Bardy, MDSeattle Institute for Cardiac ResearchBellevue, WA

Denise D. Barnard, MDUniversity of California, San DiegoSan Diego, CA

Donald M. Bers, PhDUniversity of California, DavisDavis, CA

Lenore J. Blank, RN, MSN, NP-CMahwah, NJ

Burns C. Blaxall, PhDUniversity of RochesterWest Henrietta, NY

Ann Bolger, MDUniversity of California, San FranciscoSan Francisco, CA

Jeffrey S. Borer, MDSUNY Downstate Medical CenterBrooklyn, NY

Robert C. Bourge, MDUniversity of Alabama at BirminghamBirmingham, AL

Steven W. Boyce, MDWashington Regional Cardiac Surgery, PCWashington, DC

Biykem Bozkurt, MDBaylor College of Medicine Houston, TX

Eugene Braunwald, MDBrigham and Women’s HospitalBoston, MA

Michael R. Bristow, MD, PhDUniversity of ColoradoAurora, CO

Harleah G. Buck, RN, PhD, CHPNThe Pennsylvania State UniversityUniversity Park, PA

Daniel Burkhoff, MD, PhDColumbia UniversityNew York, NY

Javed Butler, MD, MPHEmory UniversityAtlanta, GA

Peter Buttrick, MDUniversity of ColoradoAurora, CO

James H. Caldwell, MDUniversity of WashingtonSeattle, WA

Thomas P. Cappola, MD, ScMUniversity of PennsylvaniaPhiladelphia, PA

Blase A. Carabello, MDVA Medical CenterHouston, TX

Peter E. Carson, MDWashington VAMCWashington, DC

Donald E. Casey, Jr., MD, MPH, MBAAtlantic Health SystemMorristown, NJ

Horng H. Chen, MB, BChMayo Clinic and FoundationRochester, MN

Suzanne Chillcott, BSN, RNSharp Memorial HospitalSan Diego, CA

John Chin, MDSutter Memorial HospitalSacramento, CA

Dawn M. Christensen, MS, FNP-BC, ACNP-BCPenn State UniversityHershey, PA

Eugene S. Chung, MDThe Ohio Heart and Vascular CenterCincinnati, OH

John G.F. Cleland, MDUniversity of HullKingston-Upon-Hull, United Kingdom

Barbara A. Cockrill, MDBrigham and Women’s HospitalBoston, MA

Robert J. Cody, MBA, MDMerck & Co., Inc.Whitehouse Station, NJ

Jay N. Cohn, MDUniversity of Minnesota Minneapolis, MN

Billy CollinsSteven Barclay AgencyPetaluma, CA

Monica M. Colvin-Adams, MD, MSUniversity of MinnesotaMinneapolis, MN

William G. Cotts, MDNorthwestern UniversityChicago, IL

Jennifer Cowger, MD, MSUniversity of MichiganAnn Arbor, MI

Sharlene M. Day, MDUniversity of MichiganAnn Arbor, MI

Teresa De Marco, MDUniversity of California, San FranciscoSan Francisco, CA

Prakash C. Deedwania, MDVA Central California Health Care SystemFresno, CA

Colleen Delaney, RN, PhD, AHN-BCUniversity of ConnecticutStorrs, CT

Mario C. Deng, MDUCLALos Angeles, CA

David DeNofrio, MDTufts Medical CenterBoston, MA

Akshay S. Desai, MDBrigham and Women’s HospitalBoston, MA

Anita Deswal, MD, MPHBaylor College of MedicineHouston, TX

Marcelo F. Di Carli, MDBrigham and Women’s HospitalBoston, MA

Michael G. Dickinson, MDWest Michigan HeartGrand Rapids, MI

Kenneth Dickstein, MD, PhDUniversity of BergenStavanger, Norway

Lynn V. Doering, DNScUCLALos Angeles, CA

Kathleen A. Dracup, RN, DNScUniversity of California, San FranciscoSan Francisco, CA

Mark H. Drazner, MDUniversity of Texas SouthwesternDallas, TX

Anique Ducharme, MD, MScMontreal Heart InstituteMontreal, Quebec, Canada

Mark E. Dunlap, MDMetroHealth Medical Center Cleveland, OH

Jean-Bernard Durand, MDUniversity of TexasHouston, TX

Victor J. Dzau, MDDuke UniversityDurham, NC

Uri Elkayam, MDLAC+USC Medical CenterLos Angeles, CA

Jill Howie Esquivel, RN, PhD, NPUniversity of California, San FranciscoSan Francisco, CA

Lorraine S. Evangelista, RN, PhDUniversity of California, IrvineIrvine, CA

Michael D. Ezekowitz, MB, ChB, DPhilLankenau Medical CenterWynnewood, PA

James C. Fang, MDCase Western UniversityCleveland, OH

Arthur M. Feldman, MD, PhDTemple UniversityPhiladelphia, PA

G. Michael Felker, MDDuke UniversityDurham, NC

Mona Fiuzat, PharmDDuke UniversityDurham, NC

Gregg C. Fonarow, MDUCLALos Angeles, CA

Thomas Force, MDTemple UniversityPhiladelphia, PA

Paul R. Forfia, MDUniversity of PennsylvaniaPhiladelphia, PA

Daniel Forman, MDBrigham and Women’s HospitalBoston, MA

Gary S. Francis, MDUniversity of MinnesotaMinneapolis, MN

Robert P. Frantz, MDMayo Clinic and FoundationRochester, MN

Marie Galvao, MSN, ANP-BC, CHFNMontefiore Medical CenterBronx, NY

Lior Gepstein, MD, PhDTechnion-Israel Institute of TechnologyHaifa, Israel

Robert E. Gerszten, MDMassachusetts General HospitalCharlestown, MA

advance program: confirmed Faculty

998

Charles E. Murry, MD, PhDUniversity of Washington Seattle, WA

Sanjiv M. Narayan, MD, PhDUniversity of California, San DiegoLa Jolla, CA

Tien M.H. Ng, PharmDUniversity of Southern CaliforniaLos Angeles, CA

Anju Nohria, MDBrigham and Women’s HospitalBoston, MA

John B. O’Connell, MDHeart Failure ConsultantsAtlanta, GA

Christopher M. O’Connor, MDDuke UniversityDurham, NC

Eric N. Olson, PhDUniversity of Texas SouthwesternDallas, TX

Anjali Tiku Owens, MDUniversity of PennsylvaniaPhiladelphia, PA

Milton Packer, MDUniversity of Texas SouthwesternDallas, TX

Robert Lee Page, II, PharmD, MSPHUCHSC School of PharmacyAurora, CO

Peter S. Pang, MDNorthwestern UniversityChicago, IL

Soon J. Park, MDMayo Clinic and FoundationRochester, MN

Ayan R. Patel, MDTufts Medical CenterBoston, MA

J. Herbert Patterson, PharmDUniversity of North CarolinaChapel Hill, NC

Sara C. Paul, RN, MSN, DNPWestern Piedmont Heart CentersHickory, NC

Dudley J. Pennell, MD, FRCPRoyal Brompton and Harefield NHS TrustLondon, United Kingdom

Pamela N. Peterson, MD, MSPHUniversity of ColoradoDenver, CO

Michael G. Petty, RN, CCNS, PhDUniversity of MinnesotaMinneapolis, MN

George J. Philippides, MDBoston UniversityBoston, MA

Mariann R. Piano, RN, PhDUniversity of IllinoisChicago, IL

Philippe Pibarot, DVM, PhDInstitut Universitaire de Cardiologie et de Pneumologie de Quebec Quebec, QC, Canada

Ileana L. Piña, MDAlbert Einstein College of Medicine Bronx, NY

Peipei Ping, PhDUCLALos Angeles, CA

Bertram Pitt, MDUniversity of MichiganAnn Arbor, MI

Jeanne E. Poole, MDUniversity of WashingtonSeattle, WA

Michael A. Portman, MDSeattle Children’sSeattle, WA

Susan J. Pressler, RN, PhDUniversity of MichiganAnn Arbor, MI

Margaret M. Redfield, MDMayo Clinic and FoundationRochester, MN

Shelby D. Reed, PhD, RPhDuke UniversityDurham, NC

Michael W. Rich, MDWashington UniversitySt. Louis, MO

Barbara J. Riegel, RN, DNScUniversity of PennsylvaniaPhiladelphia, PA

Jo Ellen Rodgers, PharmDThe University of North CarolinaChapel Hill, NC

Joseph G. Rogers, MDDuke UniversityDurham, NC

Paul Rosenberg, MDDuke UniversityDurham, NC

Denis Roy, MDMontreal Heart InstituteMontreal, QC, Canada

Stuart D. Russell, MDJohns Hopkins UniversityBaltimore, MD

Jason W. Ryan, MDUniversity of ConnecticutFarmington, CT

Hani N. Sabbah, PhDHenry Ford Health SystemDetroit, MI

Mitchell T. Saltzberg, MDChristiana Care HospitalNewark, DE

William H. Sauer, MDUniversity of ColoradoAurora, CO

Mitzi M. Saunders, RN, PhD, ACNS-BCUniversity of Detroit MercyDetroit, MI

Douglas B. Sawyer, MD, PhDVanderbilt UniversityNashville, TN

Leslie A. Saxon, MDUniversity of Southern CaliforniaLos Angeles, CA

Kristen G. Schaefer, MDDana-Farber Cancer InstituteBoston, MA

Douglas D. Schocken, MDDuke UniversityDurham, NC

Soko Setoguchi-Iwata, MD, MPHDuke UniversityDurham, NC

Marc A. Silver, MDChrist Hospital and Medical CenterOak Lawn, IL

Jagmeet P. Singh, MD, PhDMassachusetts General HospitalBoston, MA

Jared L. Skillings, PhDPine Rest Northeast ClinicGrand Rapids Charter Township, MI

Michael J. Sole, MDToronto General HospitalToronto, ON, Canada

Randall C. Starling, MD, MPHCleveland Clinic FoundationCleveland, OH

Josef Stehlik, MD, MPHUniversity of Utah HospitalSalt Lake City, UT

Lynne Warner Stevenson, MDBrigham and Women’s HospitalBoston, MA

William G. Stevenson, MDBrigham and Women’s HospitalBoston, MA

Garrick C. Stewart, MDBrigham and Women’s HospitalBoston, MA

Wendy Gattis Stough, PharmDExpert Medical Communications & Consulting, LLCCary, NC

Mark D. Sullivan, MD, PhDUniversity of WashingtonSeattle, WA

Nancy K. Sweitzer, MD, PhDUniversity of WisconsinMadison, WI

Mario Talajic, MDMontreal Heart InstituteMontreal, QC, Canada

W.H. Wilson Tang, MDCleveland Clinic FoundationCleveland, OH

David O. Taylor, MDCleveland Clinic FoundationCleveland, OH

John R. Teerlink, MDSan Francisco VAMCSan Francisco, CA

Andre Terzic, MD, PhDMayo Clinic and Foundation Rochester, MN

Jeffrey J. Teuteberg, MDUniversity of PittsburghPittsburgh, PA

Rong Tian, PhD, MDUniversity of WashingtonSeattle, WA

Robin J. Trupp, RN, PhD, APRN-BCComprehensive CV ConsultingTampa, FL

Emily J. Tsai, MDTemple UniversityPhiladelphia, PA

Carsten Tschöpe, MDCharite - University Medicine BerlinBerlin, Germany

Patricia A. Uber, PharmDUniversity of MarylandBaltimore, MD

James E. Udelson, MDTufts Medical CenterBoston, MA

Mary N. Walsh, MDSt. Vincent Heart Center of IndianaIndianapolis, IN

Thomas J. Wang, MDMassachusetts General HospitalBoston, MA

Yibin Wang, PhDUCLALos Angeles, CA

Robert G. Weiss, MDJohns Hopkins UniversityBaltimore, MD

Cheryl A. Westlake, RN, PhDAsuza Pacific UniversitySan Clemente, CA

Bruce L. Wilkoff, MDCleveland Clinic FoundationCleveland, OH

Suzanne J. Wingate, RN, PhDGaithersburg, MD

Ronald M. Witteles, MDStanford UniversityStanford, CA

Mary A. Woo, RN, DNScUCLALos Angeles, CA

Joseph Wu, MDStanford UniversityStanford, CA

Clyde W. Yancy, MD, MScNorthwestern UniversityChicago, IL

Michael R. Zile, MDMedical University of South CarolinaCharleston, SC

Mark J. Zucker, MD, JDNewark Beth Israel Medical CenterNewark, NJ

Jalal K. Ghali, MDDMC Cardiovascular Institute Detroit, MI

Mihai Gheorghiade, MDNorthwestern UniversityChicago, IL

Edward M. Gilbert, MDUniversity of Utah Health Science CenterSalt Lake City, UT

Michael M. Givertz, MDBrigham and Women’s HospitalBoston, MA

Thomas Goetz, MA, MPHBrightSight Group, LLCPrinceton, NJ

Joshua I. Goldhaber, MDCedars-Sinai Heart InstituteLos Angeles, CA

Steven Goldman, MDVA Medical CenterTucson, AZ

Steven R. Goldsmith, MDHennepin County Medical CenterMinneapolis, MN

Sarah J. Goodlin, MDPortland VAMCPortland, OR

Stephen S. Gottlieb, MDUniversity of MarylandBaltimore, MD

Barry H. Greenberg, MDUniversity of California, San DiegoLa Jolla, CA

Robert J. Gropler, MDWashington UniversitySt. Louis, MO

Michele A. Hamilton, MDCedars-Sinai Medical Center & Ronald Reagan UCLA Medical CenterLos Angeles, CA

Paul J. Hauptman, MDSt. Louis UniversitySt. Louis, MO

Adrian F. Hernandez, MDDuke UniversityDurham, NC

Ray E. Hershberger, MDUniversity of MiamiMiami, FL

J. Thomas Heywood, MDScripps ClinicLa Jolla, CA

Katherine J. Hoercher, RNCleveland Clinic FoundationCleveland, OH

Tamara B. Horwich, MDUCLALos Angeles, CA

Leora I. Horwitz, MD, MHSYale UniversityNew Haven, CT

Steven R. Houser, PhDTemple UniversityPhiladelphia, PA

Jonathan G. Howlett, MDUniversity of Calgary and Foothills Medical CenterCalgary, AB, Canada

Sharon A. Hunt, MDStanford University Stanford, CA

Claire Hunter, MDCreighton UniversityOmaha, NE

Timothy B. Icenogle, MDNorthwest Cardiothoracic and Transplant Surgeons, PSSpokane, WA

Mariell L. Jessup, MDUniversity of PennsylvaniaPhiladelphia, PA

Ranjit John, MBBSUniversity of MinnesotaMinneapolis, MN

Jacob Joseph, MB, BS, MDBrigham and Women’s HospitalBoston, MA

Corrine Y. Jurgens, RN, PhDStony Brook UniversityStony Brook, NY

Annemarie Kaan, MCN, RNThe University of British ColumbiaVancouver, BC, Canada

Stuart D. Katz, MDNew York University Langone Medicine CenterNew York, NY

James N. Kirkpatrick, MDPerelman Center for Advanced MedicinePhiladelphia, PA

Michelle M. Kittleson, MD, PhDCalifornia Heart CenterBeverly Hills, CA

Kyle W. Klarich, MDMayo Clinic and FoundationRochester, MN

Jon A. Kobashigawa, MDCalifornia Heart CenterBeverly Hills, CA

Walter J. Koch, PhDTemple UniversityPhiladelphia, PA

Marvin A. Konstam, MDTufts Medical CenterBoston, MA

Robert L. Kormos, MDUniversity of PittsburghPittsburgh, PA

Raymond Y-K Kwong, MDBrigham and Women’s HospitalBoston, MA

Neal Lakdawala, MDBrigham and Women’s HospitalBoston, MA

Rachel J. Lampert, MDYale UniversityNew Haven, CT

David E. Lanfear, MDHenry Ford HospitalDetroit, MI

Ann S. Laramee, APRNFletcher Allen Healthcare South Burlington, VT

Christopher S. Lee, RN, PhDOregon Health & Science UniversityPortland, OR

Daniel Lee, MDNorthwestern UniversityChicago, IL

Carl V. Leier, MDThe Ohio State UniversityColumbus, OH

Daniel J. Lenihan, MDVanderbilt UniversityNashville, TN

Terry A. Lennie, PhD, MSUniversity of KentuckyLexington, KY

Jane A. Leopold, MDBrigham and Women’s HospitalBoston, MA

Annarosa Leri, MDBrigham and Women’s HospitalBoston, MA

Wayne C. Levy, MDUniversity of WashingtonSeattle, WA

E. Douglas Lewandowski, PhDUniversity of IllinoisChicago, IL

Eldrin F. Lewis, MD, MPHBrigham and Women’s HospitalBoston, MA

Gregory D. Lewis, MDMassachusetts General HospitalBoston, MA

Joseph R. Libonati, PhDUniversity of PennsylvaniaPhiladelphia, PA

Giuseppe Licata, MDUniversità degli Studi di PalermoPalermo, Italy

Kelly Ann Light-McGroary, MDUniversity of IowaIowa City, IA

JoAnn Lindenfeld, MDUniversity of ColoradoAurora, CO

Peter P. Liu, MDUniversity of TorontoToronto, ON, Canada

Douglas W. Losordo, MDNorthwestern UniversityChicago, IL

W. Robb MacLellan, MDUniversity of WashingtonSeattle, WA

Calum A. MacRae, MD, PhDBrigham and Women’s HospitalBoston, MA

Alan S. Maisel, MDUniversity of California, San DiegoLa Jolla, CA

Douglas L. Mann, MDWashington UniversitySt. Louis, MO

Eduardo Marbán, MD, PhDCedars-Sinai Medical CenterLos Angeles, CA

Kenneth B. Margulies, MDUniversity of PennsylvaniaPhiladelphia, PA

Frederick A. Masoudi, MD, MSPHUniversity of ColoradoAurora, CO

Barry M. Massie, MDVA HospitalSan Francisco, CA

Simon W. Maybaum, MDMontefiore Medical CenterBronx, NY

John T. McDevitt, PhDRice UniversityHouston, TX

Edwin C. McGee, Jr., MDNorthwestern UniversityChicago, IL

Elizabeth M. McNally, MD, PhDThe University of ChicagoChicago, IL

Mandeep R. Mehra, MDBrigham and Women’s HospitalBoston, MA

JonDavid Menteer, MDUniversity of Southern CaliforniaLos Angeles, CA

Theo E. Meyer, MD, PhDUniversity of MassachusettsWorcester, MA

Alan B. Miller, MDUniversity of FloridaJacksonville, FL

Leslie W. Miller, MDUniversity of South FloridaTampa, FL

Gordon W. Moe, MDSt. Michael’s HospitalToronto, ON, Canada

Jeffery D. Molkentin, PhDCincinnati Children’s Hospital Medical CenterCincinnati, OH

Debra K. Moser, RN, DNScUniversity of KentuckyLexington, KY

Gia Mudd-Martin, PhD, MPH, RNUniversity of KentuckyLexington, KY

Mark A. Munger, PharmDUniversity of UtahSalt Lake City, UT

Michael D. Murray, PharmD, MPHRegenstrief Institute, Inc.Indianapolis, IN

advance program: confirmed Facultyadvance program: confirmed Faculty

1110

program at a glance

Sunday, September 9, 2012

10:30 AM Clinical Fundamentals: Initial Evaluation and Standard Therapies

1:00 PM Satellite Symposium Satellite Symposium Satellite Symposium Satellite Symposium

3:00 PM Joint Session ICCAC-VAD (3:30-6:00 PM)

Special Sunday Scientific Session: Excellence in Basic Science (3:30-6:00 PM)4:00 PM Satellite Symposium Satellite Symposium Satellite Symposium

6:00-8:00 PM Opening Reception 16th Annual Scientific Meeting Poster-Exhibit Area (Exhibit Hall)

Monday, September 10, 2012

8:00 AM Welcome/Opening Remarks

8:10 AM 2012 HFSA Lifetime Achievement Award

8:25 AM Presidential Address

8:40 AM Opening Plenary Session: Communication in a New World

10:00 AM Coffee Break: Exhibit Hall (posters displayed 9:30 AM-7:00 PM)

10:30 AM Symposium I: Late Breaking News

Symposium II: Window Into the Heart

Nursing Investigator Research Award Session Symposium III: Stem Cell Controversies

12:00 PM Lunch Break

12:30 PM Rapid Fire Session (12:30-1:45 PM) (5) How-to Sessions (12:30-1:30 PM)

2:00 PM Symposium IV: Management in Nursing Homes

Symposium V: Pharmacology and Pharmacokinetics 101: Applying Theory to Patient Care

JNC New Investigator: Clinical/Physiology Session

HFSA Study Session for MOC: Part I

Symposium VI: A Day in the Life

Symposium VII: Next Generation Beta-Blocker Therapy for Heart Failure: Genes, Targets, and Mechanisms

3:30 PM Coffee Break: Exhibit Hall (posters displayed 9:30 AM-7:00 PM)

4:00 PM Symposium VIII: Mineralocorticoid Receptor Antagonists (MRAs)

Symposium IX: U Shaped Curves in Heart Failure

Symposium X: The Human Genome Comes Home

Symposium XI: The Transition from Hospital to Home

HFSA Study Session for MOC: Part II

JNC New Investigator: Basic Science Session

5:30 PM Wine and hors d’oeuvres in Poster/Exhibit Area (presenters at their posters from 5:45-6:45 PM)

7:00 PM Exhibits Close (Exhibit Hall open 9:30 AM-7:00 PM)

program at a glance

Tuesday, September 11, 2012

7:00 AM Clinical Fundamentals: Management of Arrhythmia Devices, and Pulmonary Hypertension

Roundtable: Strategies for National Heart Failure Care

8:30 AM Symposium XII: Advanced Therapy: Getting It Right

Symposium XIII: Atrial Fibrillation in Heart Failure (Joint Session HRS)

Symposium XIV: Restricting Sodium: Truth or Tradition?

Symposium XV: Connecting the Dots Between the Disease and the Symptoms

Featured Oral Abstract Session

Symposium XVI: How Should We Improve Pump Function?

10:00 AM Coffee Break: Exhibit Hall (posters displayed 9:30 AM-7:00 PM)

10:30 AM Symposium XVII: Case Discussion

Symposium XVIII: Cardiac Metabolism in Heart Failure

Symposium XIX: How Can We Test New Therapies in the US?

Symposium XX: Approach to Myocarditis/Strategy to Recover LV with LVAD (HFSA/European Joint Session)

Symposium XXI: The Patient with Heart Failure and Severe Valvular Heart Disease

12:00 PM Lunch Break

12:30 PM Rapid Fire Session (12:30-1:30 PM) (5) How-to Sessions (12:30-1:30 PM)

1:45 PM Announcement of Awards

2:00 PM Hyde Park Session

Symposium XXII: Back in the Hospital

Symposium XXIII: Therapies in Development

Symposium XXIV: From Left to Right

3:30 PM Coffee Break: Exhibit Hall (Posters Displayed 9:30 AM-7:00 PM)

4:00 PM Symposium XXV: Debate Session

Symposium XXVI: Revised AHA/ACC Performance Measures and Evidence that Supports Changes

Symposium XXVII: Remodeling in Reverse

Symposium XXVIII: Drugs Don’t Work in Patients Who Don’t Take Them: Why Aren’t Patients Adherent?

5:30 PM Wine and hors d’oeuvres in Poster/Exhibit Area (presenters at their posters from 5:45-6:45 PM)

7:00 PM Exhibits Close

Wednesday, September 12, 2012

7:00 AM Clinical Fundamentals: Options for Advanced Heart Failure and Clinical Pearls

8:15 AM HFSA Business Meeting

8:30 AM Symposium XXIX: Cardiotoxicity

Symposium XXX: Advances in Diagnosis and Targeted Management Strategies of Specific Cardiomyopathies

Symposium XXXI: Decreasing Readmission From Home

10:00 AM Coffee Break: Meeting Foyer Areas

10:30 AM Symposium XXXII: Envisioning Therapy in Heart Failure

Symposium XXXIII: Re-defining Success

Symposium XXXIV: Common Sense and Personalized Medicine

12:00 PM Scientific Meeting Adjourned. 17th Annual Scientific Meeting: September 22-25, 2013, Orlando, Florida

advance program advance program

1312

advance programadvance program

SUNDAY

Sunday, September 910:30 AM-1:00 PM

Clinical Fundamentals: Initial Evaluation and Standard Therapies

Moderators: Larry A. Allen, Denver, CO Akshay S. Desai, Boston, MA

10:30 Introduction: The “Typical” PatientAkshay S. Desai, Boston, MA

10:35 History and Clinical AssessmentMark H. Drazner, Dallas, TX

10:45 Family History and Evolving Role of Genetic TestingNeal Lakdawala, Boston, MA

10:55 Imaging and Invasive Assessment of New-Heart FailureJames E. Udelson, Boston, MA

11:05 Questions

11:15 Initial Medical Therapy: Selection, Initiation, and Titration of ACE-Inhibitors, Angiotensin Receptor Antagonists and Beta-BlockersMichelle M. Kittleson, Beverly Hills, CA

11:30 The ‘Third Drug’: Aldosterone Antagonist, Isordil/Hydralazine, or ARB?William G. Cotts, Chicago, IL

11:40 Other Medical Therapy: Diuretics, Digoxin, SupplementsDenise D. Barnard, San Diego, CA

11:50 Questions and AnswersFaculty

12:00 Risk Assessment: Assessment of Functional Capacity and Role for Cardiac BiomarkersTBN

12:10 HF-PEF: Workup, Pathophysiology and ManagementPrakash C. Deedwania, Fresno, CA

12:25 Acute Decompensated Heart Failure: Practical Considerations and Approach to ManagementSteven R. Goldsmith, Minneapolis, MN


Learning Objective: Describe methods for evaluating and managing chronic and acute HF, including standard drug therapy.

SPECIAL SUNDAY SCIENTIFIC SESSION

Sunday, September 93:30-6:00 PM

Excellence in Basic Science: Rebuilding the Failing Heart

Moderators: Steven R. Houser, Philadelphia, PA Jeffrey D. Molkentin, Cincinnati, OH

3:30* Strategies to Repair the Failing Heart6th Distinguished Lecture in Basic ScienceEric N. Olson, Dallas, TX

(Award to be presented immediately following lecture)

4:30* Cardiac-Derived Stem Cells to Rebuild the Failing HeartEduardo Marban, Los Angeles, CA

5:00* Embryonic Stem Cells to Rebuild the Failing HeartCharles E. Murry, Seattle, WA

5:30* Induced Pluripotent Stem Cells for Cardiac RepairAndre Terzic, Rochester, MN

*includes 5 minute audience discussion

Learning Objective: Describe emerging strategies using stem cells or fibroblasts to repair the failing heart.

Sunday, September 93:30-6:00 PM

Joint Session with ICCAC-VAD

Moderators: Michael G. Petty, Minneapolis, MN Timothy B. Icenogle, Spokane, WA

Obtaining Consent: What Do You Tell Patients and Families Considering VAD Therapy?

3:30 Setting Expectations: Education or Sales?Jeffrey J. Teuteberg, Pittsburgh, PA

3:40 What if They Say No? Palliative Care OptionsKristen G. Schaefer, Boston, MA

3:50 Caregiver Commitment: What Does Support Entail?AnneMarie Kaan, Vancouver, BC, Canada

4:00 Discussion

How High is the Bar for a “Good” Destination?

4:10 What Predicted Survival is a “Good” Destination?Michael M. Givertz, Boston, MA

4:20 What Level of Adverse Events is Acceptable?Robert L. Kormos, Pittsburgh, PA

4:30 What Quality of Life Makes a “Good” Destination?Suzanne Chillcott, San Diego, CA

4:40 Discussion

Going Home: Support Outside the Hospital

4:50 The VAD Community Online: MyAD.comSteven W. Boyce, Washington, DC

5:00 What is the Social Support Necessary For VAD Success?Michael G. Petty, Minneapolis, MN

5:10 Discussion

Programmatic Issues

5:20 Adjusting Antiocoagulation: Striking a Balance to Prevent Embolic Stroke and GI BleedsRanjit John, Minneapolis, MN

5:30 What is a Sustainable Ratio of VAD Coordinators to Patients: In New and Established ProgramsDawn M. Christensen, Hershey, PA

5:40 Discussion

Learning Objective: Identify factors important to the success of VAD therapy and how to manage them.

MONDAY OPENING PLENARY SESSION

Monday, September 108:00-10:00 AM

8:00 Opening and Welcome RemarksSteven R. Houser, Philadelphia, PA Lynne Warner Stevenson, Boston, MA Barbara J. Riegel, Philadelphia, PA

8:10 2012 HFSA Lifetime Achievement AwardPresented by Jay N. Cohn

8:25 Presidential AddressBarry M. Massie, San Francisco, CA

Communication in a New World

Moderators: Lynne Warner Stevenson, Boston, MA Thomas Force, Philadelphia, PA

8:40 Feedback Loops Wired to Change BiologyThomas Goetz, Princeton, NJ

9:20 Reaching Out for the WordsBilly Collins, Winter Park, FL

Learning Objective: Describe ways in which communication at the personal, biological, and technological levels affect healthcare.

Monday, September 1010:30 AM-12:00 PM

Late Breaking News

Moderators: Jay N. Cohn, Minneapolis, MN Barry H. Greenberg, La Jolla, CA

10:30* TBDCommentary: TBN




*22 minutes allotted: 15 minute presentation, 8 minute commentary

Learning Objective: Describe the results of recent trials and discuss their implications for the care of patients with heart failure.


Nursing Investigator Research Award

Moderators: Kathleen A. Dracup, San Francisco, CA Susan J. Pressler, Ann Arbor, MI

5 presentations, TBD

*10 minute presentation, 8 minute audience discussion

Learning Objective: Discuss results of recent nursing research and its implications for the care of patients with HF.

1514



Window Into the Heart

Moderators: Marvin A. Konstam, Boston, MA Invited

10:30 A Perfect CycleAnn Bolger, San Francisco, CA

10:40 Metabolism Through NMRRong Tian, Seattle, WA

10:55 Shifting Substrates-PETJames H. Caldwell, Seattle, WA

11:05 Cardiac Magnetic Resonance Imaging Determines Etiology and ViabilityDaniel Lee, Chicago, IL

11:15 MIBG Imaging to Track Therapies and PrognosisJames H. Caldwell, Seattle, WA

11:30 The Picture of Myocardial InflammationPeter P. Liu, Toronto, ON, Canada


Learning Objective: Identify imaging modalities and their appropriate use in the evaluation and management of patients with heart failure.


Stem Cell Controversies

Moderators: TBN Douglas W. Losordo, Chicago, IL

CONTROVERSY

10:30 Why Do We Need iPS Cells if We Have Adult Cardiac Stem Cells?Invited

10:40 Why Do We Need Adult Cardiac Stem Cells if We Have iPS Cells?Charles E. Murry, Seattle, WA

10:55 Questions

11:00* Human iPS Cell-Based Therapy: Considerations Before Clinical ApplicationsJoseph Wu, Chapel Hill, NC

11:18* Alternative Use of Human iPS Cells: Drug Screening and Disease ModelingLior Gepstein, Haifa, Israel

11:36* Can We Reprogram Cardiac Fibroblasts Into New Cardiac MyocytesVictor J. Dzau, Durham, NC

*15 minute presentation, 2-3 minute audience discussion

Learning Objective: Describe the role and importance of iPS cells and adult stem cells in heart failure research and drug testing.

Monday, September 1012:30-1:45 PM

Rapid Fire Session

Moderators: Gary S. Francis, Minneapolis, MN Peter P. Liu, Toronto, ON, Canada

15 abstracts “rapid fire,” 3 minutes to present, 2 minute discussion

Learning Objective: Discuss findings from recent clinical research in heart failure.


How-to Sessions

1. How to Identify Treatable Causes of Heart FailureMichael M. Givertz, Boston, MADavid E. Lanfear, Detroit, MI

Learning Objective: List treatable causes of heart failure and describe clinical techniques and procedures to identify them.

2. How to Bridge Patients to Transplantation with VADsMichael A. Acker, Philadelphia, PAJosef Stehlik, Salt Lake City, UT

Learning Objective: Identify clinical issues in the management of patients with VADs awaiting transplant and how they can best be managed.

3. How to Maximize Adherence to Heart Failure Performance Measures in the Inpatient and Outpatient SettingsMarc A. Silver, Oak Lawn, ILMary N. Walsh, Indianapolis, IN

Learning Objective: Identify heart failure performance measures and describe strategies for maximizing adherence in the inpatient and outpatient settings.

4. Using Tools for Economic Analysis of Management InterventionsShelby D. Reed, Durham, NCSara C. Paul, Hickory, NC

Learning Objective: Use tools to analyze the cost and cost-effectiveness of management interventions in heart failure.

5. Difficult Conversations About PrognosisKristen G. Schaefer, Boston, MAHarleah G. Buck, University Park, PA

Learning Objective: Describe strategies for productive discussions with heart failure patients facing a difficult prognosis.


Management in Nursing Homes

Moderators: James N. Kirkpatrick, Philadelphia, PA Corrine Y. Jurgens, Stony Brook, NY

2:00* Where Does Disease Management Take Place?John B. O’Connell, Atlanta, GA

2:18* Device ManagementRachel J. Lampert, New Haven, CT

2:36* When to Hold, When to FoldAli Ahmed, Birmingham, AL

2:54* Exercise Guidelines for Heart Failure in Nursing HomesRoss Arena, Albuquerque, NM

3:12* Promoting Self-Care in Patients Discharged Home From a Skilled Nursing FacilityColleen Delaney, Storrs, CT


Learning Objective: Describe strategies for the effective evaluation and management of patients with heart failure in nursing homes.


Pharmacology and Pharmokinetics 101: Applying Theory to Patient Care

Moderators: Robert Lee Page, II, Aurora, CO Mona Fiuzat, Durham, NC

2:00* Testing New HF Drugs in Animal ModelsHani N. Sabbah, Detroit, MI

2:15* Pharmacokinetics: Heart Failure Impacts on Drug MetabolismRobert Lee Page, II, Aurora, CO

2:30* Drug-Drug Interactions: Pumps, Proteins, and P-450sJo Ellen Rodgers, Chapel Hill, NC

2:45* Pharmacodynamics: Drug-induced QT Prolongation: Is It a Concern?Tien M.H. Ng, Rochester, NY

3:00* Adapting Drug Regimens for the ElderlyMichael W. Rich, St. Louis, MO

3:15* Supplements or Prescriptions? PUFAs and OthersBarry H. Greenberg, La Jolla, CA

*12 minute presentations, 3 minute discussion

Learning Objective: Describe the pharmacology of heart failure drugs and its implications for patient management.


HFSA Study Session for MOC: Advanced Heart Failure and Transplant Cardiology Part I

(10 Knowledge Points: Must attend both sessions to earn points)

Moderators: Ileana L. Piña, Bronx, NY Invited

Learning Objective: Discuss key questions in the epidemiology, pathophysiology, and treatment of patients with advanced heart failure.


Jay N. Cohn New Investigator Award: Clinical/Integrative Physiology

Moderators: Jay N. Cohn, Minneapolis, MN Barry H. Greenberg, La Jolla, CA



Learning Objective: Discuss results of recent research and their implications for the treatment of heart failure.

1716



A Day in the Life

Moderators: Eldrin F. Lewis, Boston, MA Mary A. Woo, Los Angeles, CA

2:00 Night and Day: Hemodynamic Rhythms During Ambulatory MonitoringPhilip B. Adamson, Oklahoma City, OK

2:10 FEATURED LECTUREDiurnal Rhythms at the Translational (or Molecular) LevelMichael J. Sole, Toronto, ON, Canada

2:30 Medication Schedules to Optimize Adherence and BenefitMichael D. Murray, Indianapolis, IN

2:40 Discussion

2:45 Optimal Frequency and Intensity of ExerciseDaniel Forman, Boston, MA

3:00 Family DynamicsSusan J. Pressler, Ann Arbor, MI

3:15 Circadian Rhythms and Sleep-Disordered BreathingJames C. Fang, Cleveland, OH

3:25 Questions and Answers

Learning Objective: Use circadian rhythms and other time-based strategies to maximize management of the patient with heart failure.


Next Generation Beta-Blocker Therapy for Heart Failure: Genes, Targets, and Mechanisms

Moderators: Walter J. Koch, Philadelphia, PA J. Herbert Patterson, Chapel Hill, NC

2:00* Challenges in Beta-Blocker Utilization: Counting the EligibleAdrian F. Hernandez, Durham, NC

2:18* Biased Downstream SignalingBurns C. Blaxall, Rochester, NY

2:36* Next Generation Beta-Blockers for Heart Failure: Isoform Specific TargetingMichael R. Bristow, Denver, CO

2:54* Genetic Diversity in Beta-Blocker TherapyTBN

3:12* Beta Blockers: A Class Effect?Steven S. Gottlieb, Baltimore, MD


Learning Objective: Describe emerging ways in which the effectiveness of beta-blocker therapy for heart failure might be increased.


Mineralocorticoid Receptor Antagonists (MRAs)

Moderators: Peter E. Carson, Washington, DC Randall C. Starling, Cleveland, OH

4:00 Get with the Guidelines: Does Adherence Assure Quality Outcomes?Gregg C. Fonarow, Los Angeles, CA

4:15 MRAs: What is the Evidence to Support Their UseBertram Pitt, Ann Arbor, MI

4:30 MRAs: What are the Gaps in Adoption?Mary N. Walsh, Indianapolis, IN

4:45 HFSA 2012 Recommendations on the Use of MRAJaved Butler, Atlanta, GA

5:00 Panel Discussion and Case StudiesPanelists: Javed Butler, Atlanta, GA Peter E. Carson, Washington, DCGregg C. Fonarow, Los Angeles, CABertram Pitt, Ann Arbor, MIRandall C. Starling, Cleveland, OHWendy Gattis Stough, Cary, NCMary N. Walsh, Indianapolis, INCheryl A. Westlake, San Clemente, CA

Case #1: A 70 yo African American male with EF 30%, NYHA Class III. What is the best to add next? Presenter: Nancy K. Sweitzer, Madison, WI

Case #2: A 35 yo diabetic male post-MI with EF 36% impaired renal function. What is the best to add next and how to monitor? Presenter: Monica Colvin-Adams, Minneapolis, MN

Learning Objective: Identify updates and clinical applications of guidelines for the treatment of patients with heart failure.


U Shaped Curves in Heart Failure

Moderators: John G.F. Cleland, Kingston-Upon-Hull, UK TBN

4:00* HbA1C and Heart Failure: Targets for Diabetes in Heart FailureDavid Aguilar, Houston, TX

4:15* BMI and Heart Failure: To Gain Weight or Lose it?Stefan D. Anker, Berlin, Germany

4:30* Blood Pressure in Heart Failure: Sign of Pump or Sign of Load?Biykem Bozkurt, Houston, TX

4:45* Contractility: It Has To Be Just RightSteven R. Houser, Philadelphia, PA

5:00* ICD Benefit and Disease Severity in Heart FailureLeslie A. Saxon, Los Angeles, CA

5:15* Iron and Erythropoietin in Heart Failure: What is Too Much?Inder S. Anand , Minneapolis, MN

*12 minutes with 3 minute discussion after each presentation

Learning Objective: Describe a common pattern in diverse management issues and how it provides guidance for optimum patient care.


The Human Genome Comes Home

Moderators: TBN Thomas P. Cappola, Philadelphia, PA

4:00* Common Heritable Mutations in CMRay E. Hershberger, Miami, FL

4:18* GWAs (Genome-Wide Association Studies) for DummiesThomas J. Wang, Boston, MA

4:36* Genes Causing Both CM and ArrhythmiasCalum A. MacRae, Boston, MA

4:54* Correlating Genotype with Phenotype in CardiomyopathiesSharlene M. Day, Ann Arbor, MI

5:12* Whole Genome Strategies for CardiomyopathyElizabeth M. McNally, Chicago, IL


Learning Objective: Discuss current research in the role of genetics in the development of cardiomyopathy and its implications for clinical practice.


The Transition from Hospital to Home

Moderators: Claire Hunter, Omaha, NE Alan B. Miller, Jacksonville, FL

4:00 Reducing Readmissions: What Can We All Agree On?Leora Horwitz, New Haven, CT

4:10 Does Very Early Follow-up Make a Difference?Robin J. Trupp, Tampa, FL

4:20 Paving the Road Through RehabilitationMichael G. Dickinson, Grand Rapids, MI

4:30 Questions on the Transition

4:50 Assessment and Impact of FrailtyJoAnn Lindenfeld, Denver, CO

5:00 Management in MontrealAnique Ducharme, Montreal, QC, Canada

5:10 Where is the Medical Home for Medicare Patients With Heart Failure and Co-Morbidities?Invited

5:20 Discussion

Learning Objective: Identify factors affecting the transition from hospital to home for patients with heart failure and describe ways to manage them.


HFSA Study Session for MOC: Advanced Heart Failure and Transplant Cardiology Part II

(10 Knowledge Points: Must attend both sessions to earn points)

Moderators: Ileana L. Piña, Bronx, NY Invited

Learning Objective: Discuss key questions in the epidemiology, pathophysiology, and treatment of patients with advanced heart failure.


Jay N. Cohn New Investigator Award: Basic Science

Moderators: Walter J. Koch, Philadelphia, PA TBN



Learning Objective: Discuss the results and implications of basic science research in heart failure.

1918


TUESDAY

Tuesday, September 117:00-8:15 AM

Strategies for National Heart Failure Care

Moderators: Clyde W. Yancy, Chicago, IL

7:00 The View from WashingtonMarvin A. Konstam, Boston, MABarry H. Greenberg, La Jolla, CA

7:15 How Many Patients, How Many Staff?Mariell L. Jessup, Philadelphia, PA

7:23 Nurses, Nurse Practitioners, or Physician AssistantsSuzanne J. Wingate, Gaithersburg, MD

7:31 What Costs for Transplant and VADS are Sustainable?Joseph G. Rogers, Durham, NC

7:39 The Michigan ModelKeith D. Aaronson, Ann Arbor, MI

7:47 The VA System as a Database ModelBarry M. Massie, San Francisco, CA

7:55 Panel Discussion

Learning Objective: Identify factors affecting the transition from hospital to home for patients with heart failure and describe ways to manage them.


Clinical Fundamentals: Management of Arrhythmia Devices, and Pulmonary Hypertension

Moderators: Daniel J. Lenihan, Nashville, TN Ayan R. Patel, Boston, MA

7:00 CRT – Wider Indications, Wider QRSJagmeet P. Singh, Boston, MA

7:10 ICD-Common and Uncommon Indications and ComplicationsSanjiv Narayan, La Jolla, CA

7:20 ICD Shocks: Evaluating and Secondary PreventionWilliam G. Stevenson, Boston, MA

7:30 Device Questions

7:40 Evaluation of Pulmonary Hypertension and Right Ventricular FunctionMyung H. Park, Baltimore, MD

7:50 Specific Causes of Pulmonary HypertensionTeresa De Marco, San Francisco, CA

8:00 Newer Management of Primary and Secondary Pulmonary HypertensionRobert P. Frantz, Rochester, MN

8:10 Questions

Learning Objective: Describe strategies for care of the patient with advanced heart failure, including mechanical circulatory support and transplantation.


Advanced Therapy: Getting It Right

Moderators: Sharon A. Hunt, Stanford, CA Leslie W. Miller, Tampa, FL

8:30 Referral to Advanced Heart Failure ProgramsMark J. Zucker, Newark, NJ

8:40 Significance of ICD Shocks for PrognosisJeanne E. Poole, Seattle, WA

8:50 Listing for Transplant Depends on Length of ListMario C. Deng, Los Angeles, CA

9:00 Serial Monitoring of the Right Ventricle During HF ProgressionPaul R. Forfia, Philadelphia, PA

9:10 Not Too Sick or Too Well for a VADMichael A. Acker, Philadelphia, PA

9:20 Discussion

9:30 Preventing Rejection and Vasculopathy Without Infection or CancerDavid O. Taylor, Cleveland, OH

9:40 Questions

9:45 Too Soon or Too Late for the Hospice DiscussionKelly Ann Light-McGroary, Iowa City, IA

9:55 Questions

Learning Objective: Describe approaches to key management decisions in care of the patient with advanced heart failure.


Atrial Fibrillation in Heart FailureJoint Session with HRS

Moderators: William G. Stevenson, Boston, MA Jagmeet P. Singh, Boston, MA

8:30 Prevalence of Atrial Fibrillation in HF All EFDenis Roy, Montreal, QC, Canada

8:45 Anticoagulation in AF: Dosing New and OldMichael D. Ezekowitz, Wynnewood, PA

9:00 Anxiety Sensitivity and Benefit of AF Rhythm ControlMario Talajic, Montreal, QC, Canada

9:15 Questions

Three Approaches to Atrial Fibrillation

9:20 Anti-arrhythmic Drugs and Rate ControlWilliam G. Stevenson, Boston, MA

9:30 Ablation of the Atrial FibrillationSanjiv Narayan, La Jolla, CA

9:40 AV Node Ablation and CRTBruce L. Wilkoff, Cleveland, OH

9:50 Discussion

Learning Objective: Recognize clinical issues in the care of patients with atrial fibrillation and choose the best management options.


Restricting Sodium: Truth or Tradition?

Moderators: Biykem Bozkurt, Houston, TX Bertram Pitt, Ann Arbor, MI

8:30 Hyponatremia: Marker or Target?James E. Udelson, Boston, MA

Point/Counter Point

8:40 Sodium Restriction is Beneficial in Patients with Heart FailureStuart D. Katz, New York, NY

8:50 Sodium Restriction Can Be Harmful in Patients with Heart FailureGiuseppe Licata, Palermo, Italy

9:00 Discussion

9:05 Can We Develop a Drug to Diminish ThirstRobert J. Cody, Whitehouse Station, NJ

9:22 Discussion

9:25 Fluid Restriction in Patients with Heart Failure: When is it Needed?J. Thomas Heywood, La Jolla, CA

9:45 One Size Does Not Fit AllTerry A. Lennie, Lexington, KY

9:55 Questions

Learning Objective: Discuss what is known about the role of sodium restriction in heart failure and selected strategies for successful implementation.


Connecting the Dots Between the Disease and the Symptoms

Moderators: Katherine J. Hoercher, Cleveland, OH Mark D. Sullivan, Seattle, WA

8:30 How Does EF Affect the Symptoms of Heart Failure?Michael R. Zile, Charleston, SC

8:40 Who Knows Best? Using The Patient Symptom ReportCorrine Y. Jurgens, Stony Brook, NY

8:50 I am Short of Breath – Clinical and Hemodynamic DiagnosisStuart D. Russell, Baltimore, MD

9:05 BNP Fragments: Potent or Passengers?Horng H. Chen, Rochester, MN

9:15 Discussion of Diagnosis

9:20 Tracking Changes at HomeEugene S. Chung, Cincinnati, OH

9:35 PDE-5 Inhibitors – Treating the Disease or the Symptoms?Gregory D. Lewis, Boston, MA

9:45 Symptom Burden and PalliationJames N. Kirkpatrick, Philadelphia, PA

9:55 Questions

Learning Objective: Describe the physiological basis of heart failure symptoms and the role of selected symptoms in patient care.


How Should We Improve Pump Function?

Moderators: Burns C. Blaxall, Rochester, NY Douglas L. Mann, St. Louis, MO

8:30* Contractility Modulation or Smaller Assist Devices for Earlier Use?Daniel Burkhoff, New York, NY

8:45* Autonomic Modulation – For The Periphery or The Heart?Mark E. Dunlap, Cleveland, OH

9:00* New Targets for Inotropic TherapyWalter J. Koch, Philadelphia, PA

9:15* How Can Negative Inotropic Agents Improve Cardiac FunctionJoshua I. Goldhaber, Los Angeles, CA

9:30* IV Inotropic Therapy at HomeLenore J. Blank, Mahwah, New Jersey

9:45* Can CaMKII Inhibitors Affect the Function of the Failing Heart? Donald M. Bers, Davis, CA

*12 minute presentation, 3 minute discussion

Learning Objective: Describe ways in which emerging devices and inotropic therapy can impact cardiac function in heart failure.


Featured Oral Abstract Session

Moderators: Lynne V. Doering, Los Angeles, CA Javed Butler, Atlanta, GA

6 abstracts, TBD

*15 minutes each (10 minute presentation, 5 minute discussion)

Learning Objective: Discuss findings from recent research in heart failure and their implications for heart failure research and treatment.

Tuesday, September 1110:30 AM-12:00 PM

Case Discussion

Case Presenters: James C. Fang, Cleveland, OH Gary S. Francis, Minneapolis, MN

Panelists: Michele A. Hamilton, Los Angeles, CA Soon J. Park, Rochester, MN Patricia A. Uber, Baltimore, MD Sara C. Paul, Hickory, NC Mario Talajic, Montreal, QC, Canada

Learning Objective: Using practice guidelines, research findings and clinical experience, make decisions about the management of difficult cases in heart failure.

2120



Cardiac Metabolism in Heart Failure

Moderators: Michael A. Portman, Seattle, WA TBN

10:30* Metabolic Remodeling in Human Heart FailureRobert J. Gropler, St. Louis, MO

10:48* Novel Metabolic Therapies on the Horizon?E. Douglas Lewandowski, Chicago, IL

11:06* Mitochondrial Metabolism in HFW. Robb MacLellan, Seattle, WA

11:34* Metabolic Therapeutics in the Failing HeartRobert G. Weiss, Seattle, WA

11:52* Perturbations of Mitochondrial Proteome in the Failing MyocardiumPeipei Ping, Los Angeles, CA


Learning Objective: Describe the role of cardiac metabolism in remodeling and cardio-protection and the role of emerging metabolic therapies.


How Can We Test New Therapies in the US?

Moderators: Mihai Gheorghiade, Chicago, IL TBN

10:30 IntroductionMihai Gheorghiade, Chicago, IL

10:35 Industry Point of ViewTBNTBN

11:05 FDA Point of ViewFelipe Aguel, Silver Spring, MD

11:30 European Drugs/Devices Ahead of the USKenneth Dickstein, Stavanger, Norway


Learning Objective: Describe the role of national policies on the development of new heart failure therapies in the US and Europe and discuss ways to enhance research and development.


Approach to Myocarditis/Strategy to Recover LV with LVADHFSA/European Joint Session

Moderators: Invited Barry M. Massie, San Francisco, CA

Role of Anti-myocardia Abs: Cause or Result of Injury?

10:30 Anti-myocardial Antibodies and Persistent Virus in CardiomyopathyCarsten Tschöpe, Berlin, Germany

10:45 The Role of Biopsy and Testing for AntibodiesInvited

11:00 Discussion

Recovery is Real with VADs

11:15 European Experience with VAD Recovery – Different Patients or Different Patience?Invited

11:30 US Experience with RecoverySimon W. Maybaum, Bronx, NY

11:45 Discussion

Learning Objective: TBD


The Patient with Heart Failure and Severe Valvular Heart Disease

Moderators: Blase A. Carabello, Houston, TX Invited

10:30 The Low Gradient Low EF AS PatientPhilippe Pibarot, Quebec, QC, Canada

10:45 Dogs and People with Functional MRBlase A. Carabello, Houston, TX

11:00 The Patient with Advanced ARJeffrey S. Borer, Brooklyn, NY

11:15 The Patient with Valvular Heart Disease and Lung Disease: When Will Fixing the Valve Fix the Dyspnea?Barbara A. Cockrill, Boston, MA

11:30 Can I Ignore TR in My Patient with Left-Sided Valvular Heart Disease?Edwin C. McGee, Jr., Chicago, IL


Learning Objective: Describe surgical approaches to the heart failure patient with valvular disease.

Tuesday, September 1112:30-1:30 PM

Rapid Fire Session

Moderators: Arthur M. Feldman, Philadelphia, PA Carl V. Leier, Columbus, OH

12 abstracts “rapid fire,” TBD

*3 minutes to present, 2 minute discussion

Learning Objective: Discuss findings from recent research in HF and their implications for heart failure research and treatment.


How-to Sessions

6. Using Apps for Self-CareJill Howie Esquivel, San Francisco, CALorraine S. Evangelista, Los Angeles, CA

Learning Objective: Describe the role of electronic applications in patient self-management of heart failure.

7. Cardiotoxicity of Chemotherapy: Evaluation and TherapyJean-Bernard Durand, Houston, TXAnju Nohria, Boston, MA

Learning Objective: Evaluate heart failure patients undergoing or recovering from chemotherapy and manage their disease.

8. How to Read and Interpret the Results of Genetic TestingNeal Lakdawala, Boston, MAAnjali Tiku Owens, Philadelphia, PA

Learning Objective: Identify the components of genetic testing results, their meaning, and their implications for patient care.

9. How to Identify and Use Simple Tools for Assessment of Health LiteracyPamela N. Peterson, Denver, COAnn S. Laramee, South Burhington, VT

Learning Objective: Identify and use tools to assess health literacy and improve care in patients with heart failure.

10. Heart Failure Physicians Learn to Read the ICD/CR Device ReportsBruce L. Wilkoff, Cleveland, OHTBN

Learning Objective: To identify the components in the device reports most important for managing heart failure.


Hyde Park Session

Moderators: John G.F. Cleland, Kingston-Upon-Hull, UK Douglas D. Schocken, Durham, NC

TBD


Learning Objective: Discuss new insights and perspectives on heart failure research, education, and clinical practice.


Back in the Hospital

Moderators: Anita Deswal, Houston, TX Debra K. Moser, Lexington, KY

2:00 Leading Up to Admission (ADHERE)Javed Butler, Atlanta, GA

2:15 Why is the Patient Back?Jason W. Ryan, Farmington, CT

2:25 How is Comorbidity Associated with Readmission?Jill Howie Esquivel, San Francisco, CA

2:35 What Else Can DOSE and ASCEND Teach Us?G. Michael Felker, Durham, NC

2:45 ED Decision: Admit or Discharge to Early Follow-Up?Peter S. Pang, Chicago, IL

3:00 How Much Patient Education and When?Lorraine S. Evangelista, Los Angeles, CA


Learning Objective: Describe factors affecting readmission of patients with heart failure and implement strategies to improve readmission rates.

2322



Therapies in Development

Moderators: Steven Goldman, Tucson, AZ Michael J. Sole, Toronto, ON, Canada

2:00* Where is there a Clinical Need?Arthur M. Feldman, Philadelphia, PA

2:18* PKC Inhibitors are Ready for Heart Failure Trials!Jeffrey D. Molkentin, Cincinnati, OH

2:36* Enough with the Kinases; Phosphatase Inhibitors for Heart Failure TherapyYibin Wang, Los Angeles, CA

2:54* Cell-Free Regenerative TherapiesAnnarosa Leri, Boston, MA

3:12* Angiogenesis for Ischemic Heart DiseaseDouglas W. Losordo, Chicago, IL


Learning Objective: Describe emerging therapies for heart failure and how they might be used to improve patient care.


From Left to Right

Moderators: Paul R. Forfia, Philadelphia, PA Robert P. Frantz, Rochester, MN

2:00* Pulmonary Hypertension From HFpEFMargaret M. Redfield, Rochester, MN

2:15* Primary, Reactive or Passive Pulmonary HypertensionTBN

2:30* Lessons from Experimental Pulmonary HypertensionJane A. Leopold, Boston, MA

2:45* What Does the Right Ventricle Look Like?TBN

3:00* Animal Models of Right Ventricle OverloadEmily J. Tsai, Philadelphia, PA

3:15* Right Ventricular RecoveryMandeep R. Mehra, Boston, MA


Learning Objective: Describe pulmonary hypertension and right ventricular failure and identify appropriate management options.


Debate Session

Moderators: Marvin A. Konstam, Boston, MA Lynne Warner Stevenson, Boston, MA

DEBATE: Oral Inotropic Agents Should be Available for Palliative Care

4:00 Pro: Milton Packer, Dallas, TX

4:15 Con: Milton Packer, Dallas, TX

4:30 Questions from Moderators

DEBATE: Clinical Care

4:45 Clinical Care Should Focus More on Risk Stratification Tools*Wayne C. Levy, Seattle, WA

5:00 Clinical Care Should Focus on More on Tools For Assessing Quality of Life*John A. Spertus, Kansas City, MO

*Equal time should be given to all recognized tools.

5:15 Questions from Moderators

Learning Objective: Outline considerations influencing the use of inotropic agents in palliative care and tools for assessing risk and quality of life in patients with heart failure.


Revised AHA/ACC Performance Measures and Evidence That Supports Changes

Moderators: Nancy M. Albert, Cleveland, OH Mariell L. Jessup, Philadelphia, PA

4:00 Impact of Performance Measures on OutcomesChristopher M. O’Connor, Durham, NC

4:10 Heterogeneity of PerformanceGregg C. Fonarow, Los Angeles, CA

4:20 Can We Adjust Populations to Measure Effectiveness?Soko Setoguchi-Iwata, Durham, NC

4:30 When Guidelines Can Be Performance MeasuresFrederick A. Masoudi, Aurora, CO

4:40 What the Community Physician Needs to KnowDonald E. Casey, Jr., Morristown, NJ

5:00 Strategy for Implementation of Outpatient MeasuresClyde W. Yancy, Chicago, IL


Learning Objective: Identify and assess current performance measures in heart failure and implement strategies for adherence.


Remodeling in Reverse

Moderators: Michael R. Bristow, Denver, CO Douglas L. Mann, St. Louis, MO

4:00 Changing Gene Expression with MedicationsPeter Buttrick, Denver, CO

4:15 Changing Gene Expression with LVAD SupportKenneth B. Margulies, Philadelphia, PA

4:30 Questions

4:35 The Dynamic Right VentricleMichael R. Bristow, Denver, CO

4:50 Questions

4:55 What Happens to Ventricular Function with Heart Failure Self CareChristopher S. Lee, Portland, OR

5:10 Hemodynamic Remodeling During Home MonitoringWilliam T. Abraham, Columbus, OH

5:25 Questions

Learning Objective: Describe ways in which therapy can influence the genetic and physiological basis of heart failure and improve patient care.


Drugs Don’t Work in Patients Who Don’t Take Them: Why Aren’t Patients Adherent?

Moderators: TBN Robert Lee Page, II, Aurora, CO

4:00 How Can Medication Adherence be Measured?Patricia A. Uber, Baltimore, MD

4:18 Dosing RegimensMichael D. Murray, Indianapolis, IN

4:36 Predicting NonadherenceBarbara J. Riegel, Philadelphia, PA

4:54 Consequences of Poor AdherencePaul J. Hauptman, St. Louis, MO

5:12 What Can We Do to Improve Adherence?Debra K. Moser, Lexington, KY

Learning Objective: Measure patient adherence, identify variables contributing to non-adherence, and implement measures to improve adherence.

WEDNESDAY

Wednesday, September 127:00-8:30 AM

Clinical Fundamentals: Options for Advanced Heart Failure and Clinical Pearls

Moderators: Tamara B. Horwich, Los Angeles, CA Josef Stehlik, Salt Lake City, UT

7:00 When Is It Appropriate to Consider Referral for Advanced Heart Failure Therapies?Garrick C. Stewart, Boston, MA

7:10 A Bridge to What? Choosing the Right DestinationJennifer Cowger, Ann Arbor, MI

7:20 Mechanical Circulatory Support: Complications and TroubleshootingMichael A. Acker, Philadelphia, PA

7:35 Cardiac Transplantation: Short- and Long-Term Outcomes and Implications for Patient SelectionDavid DeNofrio, Boston, MA

7:45 Cardiac Transplantation: Individualizing Immune SuppressionJon A. Kobashigawa, Los Angeles, CA

8:00 Palliative Care and Shared Decision Making in Advanced Heart FailureSarah J. Goodlin, Portland, OR


8:15 Clinical PearlsCarl V. Leier, Columbus, OH

Learning Objective: Evaluate heart failure patients for device implantation, manage implanted devices, and diagnose and treat pulmonary hypertension.

2524



Cardiotoxicity

Moderators: Anju Nohria, Boston, MA Paul Rosenberg, Durham, NC

8:30* Why So Many Tyrosine Kinases?Thomas Force, Philadelphia, PA

8:45* Cardiac Effects of CytokinesDouglas L. Mann, St. Louis, MO

9:00* Cardiomyopathy of Substance AbuseGeorge G. Philippides, Boston, MA

9:15* Decreasing Toxicity of AnthracyclinesDouglas B. Sawyer, Nashville, TN

9:30* Toxicity of Nitric OxideTBN

9:45* Cardiac Risk of High Intensity ExerciseJoseph R. Libonati, Philadelphia, PA


Learning Objective: Evaluate heart failure patients for device implantation, manage implanted devices, and diagnose and treat pulmonary hypertension.


Advances in Diagnosis and Targeted Management Strategies of Specific Cardiomyopathies

Moderators: Edward M. Gilbert, Salt Lake City, UH Jacob Joseph, Boston, MA

8:30 Current Management Strategies in Peripartum CardiomopathyUri Elkayam, Los Angeles, CA

8:45 New Diagnostic and Management Strategies in Cardiac Amyloidosis: From Transthyretin Mutations to Bone Marrow or Liver TransplantTBN

9:00 Treatment of Thalassemia and Iron Load Cardiomyopathies: What is New?JonDavid Menteer, Los Angeles, CA

9:15 Prevention and Monitoring of Chemotherapy Induced CardiomyopathiesJean-Bernard Durand, Houston, TX

9:30 Rhythm Devices for SarcoidosisWilliam H. Sauer, Aurora, CO

9:45 Panel Discussion: Role of Registries for Specific Conditions

Learning Objective: Diagnose selected cardiomyopathies and evaluate available treatment strategies.


Decreasing Readmission from Home

Moderators: Peter E. Carson, Washington, DC Mariann R. Piano, Chicago, IL

8:30* Facing the Front Line: Use of Community Health WorkersGia Mudd-Martin, Lexington, KY

8:43* Integrating Care of Depression and Anxiety Into the ClinicJared L. Skillings, Grand Rapids, MI

8:56* Value Based Purchasing – Objects in Your Mirror Are Closer Than You Think!Mitchell T. Saltzberg, Newark, DE


9:10 Old and New Biomarkers for Triage or Therapy?Alan S. Maisel, La Jolla, CA

9:23 Update on Diuretic Infusions for Frequent FlyersMarie Galvao, Bronx, NY

9:35 Non-Invasive Monitoring is Most EffectiveJohn G.F. Cleland, Kingston-Upon-Hull, UK

9:45 Invasive Home Monitoring is Most EffectiveRobert C. Bourge, Birmingham, AL

9:55 Questions

Learning Objective: Use home-based and community-based strategies to reduce readmission of the heart failure patient.

Wednesday, September 1210:30 AM-12:15 PM

Envisioning Therapy in Heart Failure

Moderators: Eugene Braunwald, Boston, MA Gordon W. Moe, Toronto, ON, Canada

10:30 Autonomic Modulation With DevicesW.H. Wilson Tang, Cleveland, OH

10:40 The Leadless DefibrillatorGust H. Bardy, Bellevue, WA

10:50 Questions

10:55 Cardiology Patient Communities in Social NetworksLeslie A. Saxon, Los Angeles, CA

11:05 Monitoring Heart Failure Patient Symptoms and Signs through Smart PhonesTBN

11:15 Questions

11:20 Destination Therapy with Miniaturized Percutaneous VADsDaniel Burkhoff, New York, NY

11:30 Questions

11:35 Bio-Nano-Chip Technology for Biomarker Assessment in Heart FailureJohn T. McDevitt, Houston, TX

11:45 Implantable Monitoring Devices Close the Loop Directly With PatientsWilliam T. Abraham, Columbus, OH

11:55 Questions

12:00 Comments: Vision for the Future: New and RenewedEugene Braunwald, Boston, MA

Learning Objective: Discuss emerging devices and networks and their potential impact on care of patients with heart failure.


Re-defining Success

Moderators: Steven R. Goldsmith, Minneapolis, MN TBN

10:30 Better Endpoints for New TherapiesJohn R. Teerlink, San Francisco, CA

10:40 Six Minute Walk for Pulmonary Hypertension, Why Not For Heart Failure?Mandeep R. Mehra, Boston, MA

10:50 Questions

10:55 Evidence for Improved Quality of CareNancy M. Albert, Cleveland, OH

11:05 Questions

11:08 Prevalence and Prognosis of Heart Failure: Better EFAkshay S. Desai, Boston, MA

11:18 Which Medications Can Be Stopped for Improvement and How?Mark A. Munger, Salt Lake City, UT

11:28 Questions

11:35 Defining A Good DeathTheo E. Meyer, Worcester, MA

11:45 Evidence for Improving Survival in the Heart Failure PopulationJonathan G. Howlett, Calgary, AB, Canada

11:55 Questions

Learning Objective: Reassess common care endpoint in the treatment of heart failure and determine optimal approaches to care and management.


Common Sense and Personalized Medicine

Moderators: Biykem Bozkurt, Houston, TX Barbara J. Riegel, Philadelphia, PA

10:30 Do Survival Models Help in Decision Making?Larry A. Allen, Denver, CO


10:43 Do Guidelines Distinguish Inpatients from Outpatients?Sharon A. Hunt, Stanford, CA


10:56 When Do You Withhold a Recommended Therapy?Jalal K. Ghali, Detroit, MI


11:25 When Does Quality of Life Conflict with Otherwise Optimal Therapy?Ronald M. Witteles, Stanford, CA

11:40 Case DiscussionDouglas D. Schocken, Durham, NC (Moderator) Eugene S. Chung, Cincinnati, OH John Chin, Sacramento, CA

Learning Objective: Discuss optimal care of selected patients with heart failure based on evidence, guidelines, and reasonable outcomes.

2726

2012 memberSHIp appLIcaTIon

Participant: please type or print clearly. aLL information requested is required. Incomplete forms will not be processed. payment in full must

accompany registration. only one registrant per form. please make photocopies of this form for additional registrants.

name (last, first, middle initial): degree:

institution:

address:

city: state/province: zip/postal code: country:

email address:* phone: fax:

*Please enter email address carefully. It will be used for verification of attendance and access to credit certificates.

Registration Fees: To take advantage of the membership rate for the 16th annual Scientific

meeting individuals must have paid 2012 dues by June 15, 2012. See HFSa website (www.hfsa.org)

for 2012 membership application.

Members: advance after 7/30/12 code Amount

�md, do $595 $695 Fm $

� phd $495 $595 Fp $

� nurse/nurse practitioner $335 $435 Fn $

� Health professional** $335 $435 FH $

� pharmacist $335 $435 pH $

� Fda/nIH $275 $375 Fg $

� Trainee/resident* $165 $265 FT $

Nonmembers: advance after 7/30/12 code Amount

�md, do $850 $950 Fm $

� phd $720 $820 Fp $

� nurse/nurse practitioner $570 $670 Fn $

� Health professional** $570 $670 FH $

� pharmacist $570 $670 pH $

� Fda/nIH $275 $375 Fg $

� Trainee/resident* $275 $375 FT $

* student, fellow, post-doc (full-time status only, signed verification letter from program director required). Letter may

be faxed to (651) 642-1502 or emailed to [email protected]. Letters not received within 30 days of registering will result

in cancellation of meeting registration. any penalties will apply.

** dietitian, emS, nutritionist, oT, pa, pT, policy analyst, physiotherapist, technician/research technician, social worker

Payment:

Credit card: If paying by credit card you must register online. registration may be paid by american express, visa or mastercard.

Checks/Money Orders: complete the application and send with check or money order (in US dollars and from US banks only) payable to:

Heart Failure Society of america (HFSa), court International, Suite 240 South, 2550 University avenue West, St.paul, mn 55114.

Refunds: If notice of cancellation is received in writing prior to Friday, august 3, 2012, registration fee will be refunded less a $75 administrative

charge. registration cannot be transferred. no refunds will be granted after august 3, 2012.

Registration Profile: registration form will not be accepted without this section completed.

Check the category that best describes your profession:

� adult cardiologist

� pediatric cardiologist

� cv Surgeon

� ed physician

� Family/general practitioner

� Internist

� Hospitalist

� physician, other

� Scientist – phd

� Scientist (non-phd)

� pharmacist

� pharmacologist

� Technician/research Technician

� nurse/ nurse practitioner

� physician assistant

� non-medical

� other Health professionalWork Environment: (Check One)

� academic Institution

� clinic

� government

� Hospital

� Industry

� private practice

� other Health care organization

phone: (651) 642-1633 Fax: (651) 642-1502 email [email protected]

updated 06/01/2012

16th annual Scientific meeting: September 9-12, 2012Washington State convention center, Seattle, Wa

register online: www.hfsa.org (annual Scientific meeting)

Applicant: please TYpe or prInT legibly and complete ALL information requested.

name (last, first, middle initial): degree:

mailing address:

city: state/province: zip/postal code: country:

phone: fax: email address:

present hospital/university affiliation/firm/corporation:

professional education and training

(college, graduate or medical school, postgraduate training): dates attended degree

present activity in the field of heart failure:

list other society memberships:

check here if you do noT want your name, address or email to appear on mailing lists rented by

vendors/third parties

Membership: calendar year (Jan – dec). See website (www.hfsa.org) for membership benefits.

$300.00 Full members: mds, dos or equivalent who are in good standing in their respective communities,

and are actively engaged in heart failure practice or research.

$200.00 Full members (other): all nonphysicians who are in good standing in their respective communities,

and are actively engaged in heart failure practice or research.

$75.00 Trainees: open to individuals enrolled as "full-time" medical students, residents, fellows, undergraduate

students, and pre- and post-doctoral trainees. a letter of verification, including the end of training date, from the

training program direct is required with payment of dues for each year trainee membership is requested.

Previous Member? no Yes

Payment: dues may be paid with visa, mastercard, american express, check or money order (drawn

on US banks only). checks or money orders are payable to: Heart Failure Society of america.

check money order american express visa mastercard

account number: expiration date (mm/yy):

name of cardholder:

signature of cardholder:

Note: To take advantage of the membership registration rate for the 16th Annual Scientific Meeting (September 9-12, 2012, Seattle, WA) individuals must have paid 2012 dues by June 15, 2012.

Court International, Suite 240 South Tel: (651) 642-1633 2550 University Avenue West Fax: (651) 642-1502 St. Paul, MN 55114 www.hfsa.org

none of the payment is deductible as a charitable contribution but may be deductible as an ordinary and necessary business expense.

Check the category that bestdescribes your profession:(check one)

adult cardiologist

pediatric cardiologist

cv Surgeon

ed physician

Family/general practitioner

Internist

Hospitalist

physician, other

Scientist – phd

Scientist (non-phd)

pharmacist

pharmacologist

Technician/research Technician

nurse/ nurse practitioner

physician assistant

non-medical

other Health professional

Work Environment: (check one)

academic Institution

clinic

government

Hospital

Industry

private practice

other Health care organization

meeTIng regISTraTIon Form

Hea

rt F

ailu

re S

ocie

ty o

f Am

eric

a

Cou

rt In

tern

atio

nal,

Suite

240

Sou

th

2550

Uni

vers

ity A

venu

e W

est

St. P

aul,

MN

551

14

Sept

embe

r 9 –

12,

201

2W

ashi

ngto

n St

ate

Conv

entio

n Ce

nter

Seat

tle, W

Aw

ww

.hfs

a.or

g

16th

Ann

ual S

cien

tific

Mee

ting

Ad

va

nc

e P

rog

ram

& R

eg

istr

ati

on

In

form

ati

on